Chronic renal disease is a problem of increasing magnitude in the United States. This curriculum update discusses the findings in recent clinical studies of angiotensin-converting enzyme inhibition (ACE) in patients with renal disease. The results of these studies support an expanding role for ACE inhibition in the management of renal disease in increasingly diverse patient populations. The following areas are highlighted in this curriculum update:
Published by Medical Education Consultants, Inc. (MEDCON), on behalf of the University of Florida College of Medicine. Supported by an unrestricted educational grant from Wyeth-Ayerst Laboratories and Monarch Pharmaceuticals.
The editorial content of this program expresses the views of the individual contributors and does not necessarily reflect the views or recommendations of the University of Florida College of Medicine, Wyeth-Ayerst Laboratories, Monarch Pharmaceuticals, or the publisher. The indications and dosages of drugs discussed in this program may vary from those approved by the Food and Drug Administration (FDA). The reader is advised to consult the full prescribing information for each medication prior to use.